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Comparison of the Clinical 
Characteristics of Hospital-Acquired 
and Non-Hospital-Acquired 
Acinetobacter calcoaceticus-baumannii 
Complex in a Large Midwest US Health 
Care System
Juan J. Calix,1,  Jason P. Burnham,1,  and Mario F. Feldman2,
1Division of Infectious Diseases, Department of Medicine, Washington University School of 
Medicine, St. Louis, Missouri, USA, and 2Department of Molecular Microbiology, Washington 
University School of Medicine, St. Louis, Missouri, USA
We retrospectively compared the clinical characteristics of 
hospital-acquired (HA) vs non-hospital-acquired (nHA) 
Acinetobacter calcoaceticus-baumannii complex isolates in a 
large health care system in St. Louis, Missouri, from 2007 to 
2017. More than 60% of the total isolates were nHA; they were 
predominantly from nonrespiratory sources and exhibited 
~40% carbapenem resistance rates and stably persisted, though 
HA occurrence waned.
Keywords. Acinetobacter baumannii; hospital-acquired in-
fections; multidrug resistance.
The Acinetobacter calcoaceticus-baumannii complex (Abc) is a 
group of gram-negative bacteria capable of colonizing diverse 
host and abiotic environments. Abc infections exhibit high 
rates of antibiotic resistance, and the increasing prevalence of 
carbapenem-resistant A. baumannii is an urgent global health 
threat [1, 2]. The Abc is widely regarded as a group of opportun-
istic pathogens that principally cause hospital-acquired (HA) 
pneumonia and bacteremia in critically ill or immunocompro-
mised patients [3, 4]. Multiple studies, however, support that 
Abc isolates are routinely identified in outpatient settings [5–8], 
that is, that they are non-hospital-acquired (nHA). Few investi-
gations have compared contemporaneous HA and nHA Abc, so 
it remains unclear whether interventions tailored against “clas-
sical” HA Abc populations equally impact nHA counterparts. 
Here we report a retrospective longitudinal analysis of Abc 
isolates in a large, multihospital system. Notably, effective local 
interventions against nosocomial infections occurred during 




We performed a retrospective analysis of clinical isolate data 
in the BJC HealthCare System (BJC) from January 2007 to 
September 2017. BJC is a large integrated health care system 
in and around the Greater Metropolitan Area of St. Louis, 
Missouri. It includes 9 community hospitals, a pediatric hos-
pital, and a 1250-bed academic adult medical center (hereafter 
“BJC1”), totaling >3200 inpatient beds and >140  000 admis-
sions annually. For longitudinal analyses, we used full-year data 
from 2007 to 2016.
Isolate Identification and Definitions
Using the BJC Clinical Data Repository (CDR), we identi-
fied all Acinetobacter isolates obtained from individuals aged 
≥18 years as part of regular medical care. Only isolates from the 
first isolation event per patient (“index culture”) were eligible 
for inclusion. Subsequent cultures from the same patient were 
excluded. Isolates were identified using automated biochem-
ical methods or matrix-assisted laser desorption/ionization 
and time-of-flight spectroscopy. Only index cultures identi-
fied as Acinetobacter baumannii (n  =  990) or Acinetobacter 
calcoaceticus-baumannii complex (n = 1052) were included for 
analysis. Patient information, isolation source, hospital day of 
index culture (if applicable), and antibiotic susceptibility data 
were obtained from the BJC CDR and electronic chart review. 
Isolates were classified into 5 anatomical categories according 
to source: “respiratory,” “skin and soft tissue/musculoskeletal” 
(SST/MSK), “urinary,” “blood” (including isolates obtained 
from central lines, endovascular devices, or grafts), or “other.” 
Isolates were defined as HA if the index culture was performed 
≥48 hours after hospital admission and before discharge. All 
other isolates were defined as nHA.
Antibiotic Susceptibility Reporting
Antibiotic susceptibility testing was performed using the Vitek 
2 system or Kirby-Bauer disk diffusion on Mueller-Hinton 
Agar and interpreted per CLSI guidelines [9]. Due to temporal 
and hospital variation in testing practices, some antibiotic sus-
ceptibility profiles were incomplete. Isolates lacking data for 
an antibiotic were excluded from their respective analyses. 
Isolates reported as “resistant” or “intermediate” were classi-
fied as “nonsusceptible.” If an isolate was nonsusceptible to any 
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antibiotic in a class, it was labeled “nonsusceptible” for that class 
(Supplementary Table 1).
Statistical Methods
Univariate analyses were performed with SPSS, version 25 (IBM 
Corp., Armonk, NY, USA). The chi-square test or independent t test 
was performed for comparing categorical or continuous variables, 
respectively. P values <.05 were considered statistically significant.
RESULTS
Of the 2042 eligible Abc index cultures identified in BJC hos-
pitals from January 2007 to September 2017, 48.3% were from 
BJC1 and 51.7% were from other BJC hospitals (hereinafter, 
referred to as “non-BJC1” hospitals). The number of isolates 
from each anatomical source is listed in Supplementary Table 
1. As seen in Figure 1A, annual index cultures at BJC1 in-
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Figure 1. Annual occurrence and carbapenem nonsusceptibility trends among adult Abc isolates, BJC 2007–2016. A, Annual BJC1 (“BJC1,” black) and non-BJC1 (gray) 
Abc index cultures. B, Annual amounts of non-hospital-acquired (nHA; gray) and hospital-acquired (HA; black) isolates among BJC1 and non-BJC1 isolates. Black triangles 
depict annual percentages of isolates that are nHA (“nHA ratio”), and dotted lines are best-fit trend lines for annual nHA ratios (values on right y-axis). C, Carbapenem 
nonsusceptibility rate (“CRAb rate”) among all BJC, BJC1, and non-BJC1 Abc isolates. Graphs depict annual CRAb rates among total (black circles, dashed lines), HA (black 
triangles and solid line), and nHA (gray diamonds and solid line) isolates. D, CRAb rates among isolates from each anatomic source, grouped by HA (black) and nHA (gray). 
CRAb rates was compared between HA and nHA isolates. E, Proportion of carbapenem-susceptible (S), -nonsusceptible (nS), or total Abc isolates from each anatomic source. 
Isolates were grouped into HA and nHA. The proportion of isolates from each source was compared between compartments. **P < .005 by chi-square test. Black arrows in (B) 
and (C) depict the year during which a BJC1 intensive care unit that was implicated in multiple nosocomial Abc outbreaks was relocated (see text). Abbreviations: n.s., not 
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non-BJC1 index cultures remained relatively constant. Changes 
in annual BJC1 isolates were largely driven by ~70% decreases 
in annual respiratory, urinary, and blood isolates between 2009 
and 2016 (Supplementary Figure 1).
Thirty-seven point nine percent and 62.1% of all Abc isolates 
were HA and nHA, respectively (Supplementary Table 1), but 
the percentage of isolates that were nHA (“nHA ratio”) changed 
over time. Annual BJC1 HA isolates experienced a >10-fold de-
crease during 2009–2016 (Figure 1B), resulting in annual nHA 
ratios increasing from 39.2% to 74.3%. Annual BJC1 nHA iso-
lates also exhibited a ~3-fold decrease from 2009, though they 
remained relatively stable after 2012. Annual nHA ratios among 
non-BJC1 isolates averaged 78.7% and remained largely un-
changed (Figure 1B). Fifty-six point five percent of total HA 
isolates were from respiratory sources, followed by SST/MSK 
(19.1%), urinary (13.0%), blood (10.5%), and “other” (0.9%). 
In contrast, nHA isolates were primarily SST/MSK (42.9%) and 
urinary (30.4%).
As seen in Supplementary Figure 2, 2007–2011 annual nHA 
ratios among BJC1 respiratory and urinary isolates averaged 
23.5% and 61.8%, respectively. After a sharp decline in 2012, 
annual nHA ratios among BJC1 respiratory isolates varied be-
tween 15.4% and 66.7%. Contemporaneously, annual BJC1 HA 
urinary isolates decreased to 0, whereas ~10 nHA urinary iso-
lates were identified annually through 2016. The nHA ratios of 
both BJC1 and non-BJC1 blood isolates gradually increased 
over the study period. In contrast, BJC1 SST/MSK isolates and 
non-BJC1 SST/MSK, urinary, and respiratory isolates displayed 
relatively stable nHA ratios, averaging 60.4%, 83.3%, 87.5%, and 
46.8%, respectively (Supplementary Figure 2).
All groups of Abc isolates exhibited >20% antibiotic 
nonsusceptibility rates (Supplementary Table 2). Greater 
nonsusceptibility was observed among older patients, HA (vs 
nHA) isolates, and respiratory and blood (vs urinary and SST/
MSK) sources (Supplementary Table 2). All 867 carbapenem-
nonsusceptible Abc isolates were resistant to at least 2 other 
antibiotic classes. Among all Abc isolates, annual carbapenem 
nonsusceptibility rates (“CRAb rate”) ranged from 34.2% in 
2012 to 58.9% in 2009. Annual CRAb rates for nHA and HA 
isolates averaged 38.1% and 56.3%, respectively (Figure 1C). 
BJC1 CRAb rates declined beginning in 2012, averaging 58.3% 
during 2007–2011 and 36.6% during 2012–2016 (Figure 1C). 
In contrast, non-BJC1 CRAb rates were stable throughout the 
study period, averaging 39.3% (Figure 1C).
CRAb rates were comparable among HA isolates from dif-
ferent anatomic sources (Figure 1D, black bars) and were indis-
tinguishable between nHA and HA respiratory isolates (61.2% 
and 55.8%, respectively; P = .22). In contrast, CRAb rates were 
lower in nHA vs HA isolates from SST/MSK (36.7% and 63.4%, 
respectively), urinary (30.8% and 61.1%), and blood (41.2% 
and 65.3%) sources (P < .001 for all comparisons) (Figure 1D). 
Respiratory isolates composed 55.0% of HA CRAb isolates but 
only 25.8% of total nHA CRAb isolates (Figure 1E). Conversely, 
SST/MSK and urinary isolates composed 40.8% and 31.9%, re-
spectively, of nHA CRAb isolates while composing only 18.5% 
and 13.7%, respectively, of the HA CRAb reservoir. Thus, al-
though HA CRAb isolates were principally from respiratory 
sources, nHA CRAb isolates were principally from urinary and 
SST/MSK sources.
DISCUSSION
In prior cohorts, 25%–65% of Abc clinical isolates were identi-
fied within 48–72 hours of hospital admission or in the ambu-
latory setting [5–8]. Using comparable criteria, we determined 
that 60%–80% of Abc isolates in our cohort were nHA. The 
higher nHA ratio in our study may result from the inclusion 
of multiple regional community hospitals, yielding a more 
comprehensive survey of local Abc pools. Our retrospective 
database analysis was limited by not identifying which nHA 
isolates were likely health care–associated (HCA) [10]. For 
example, we could not identify whether individuals were re-
cently hospitalized, resided in long-term acute care (LTAC) fa-
cilities, or were transferred from non-BJC hospitals. However, 
important epidemiological distinctions were made between 
HA and nHA cases. First, we observed that nHA isolates were 
most often from SST/MSK or urinary sources and that HA 
isolates were predominately from respiratory sources (Figure 
1E). Though the anatomic sources of isolates are probably in-
fluenced by the variable culturing practices in each patient 
population, these associations are consistent with observa-
tions from hospitals in Hong Kong and Spain [11, 12]. Second, 
CRAb rates were lower among nHA (~40%) vs HA (~60%) 
isolates (Supplementary Table 2). This difference in resistance 
rates is consistent with observations from other US observa-
tional studies [6, 8].
An important observation is that the occurrence of nHA iso-
lates persisted even after the significant decline in BJC1 HA Abc 
cases. Multiple 2007–2012 HA isolates were obtained in a BJC1 
ICU implicated in several nosocomial outbreaks from 2007 to 
2011. The physical relocation of this ICU ward in 2012 and ro-
bust hospital-wide infection control practices coincided with 
a 10-fold decrease of annual BJC1 HA isolates. A concomitant 
3-fold decrease in nHA isolates was possibly due to an accom-
panying reduction of related HCA cases. Nevertheless, the de-
crease in HA respiratory, urinary, and blood isolates to near-0 
levels unmasked an endemic occurrence of nHA isolates with 
epidemiologic features similar to nHA isolates from non-BJC1 
hospitals (ie, urinary and SST/MSK isolates with ~40% CRAb 
rates). Consistent with the existence of nHA reservoirs, genomic 
analysis of A. baumannii isolates in another US Midwest med-
ical center suggested that transmissible isolates at 2 independent 
hospitals originated from a single, external, nonhospital pool 
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hospital environments, and the impact of nHA strains on local 
Abc disease require further investigation.
In conclusion, similar to reports from a California medical 
center [14], our findings reaffirm that control of HA infections 
is an effective way to reduce drug-resistant Abc incidence in a 
local population. However, even in the absence of local nosoco-
mial outbreaks, our Abc MDR rates remained stably above 40%. 
This highlights that the battle against MDR Abc disease must 
involve outpatient and LTAC settings, where MDR isolates are 
commonly obtained from SST/MSK and urinary sources.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility of 
the authors, so questions or comments should be addressed to the corre-
sponding author.
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